Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.


INTRODUCTION The development of selective BRAF inhibitors in patients with metastatic BRAF V600 mutant melanoma has proven to be an effective therapeutic strategy. While vemurafenib was the first approved BRAF inhibitor for this indication, another selective BRAF inhibitor, dabrafenib, has demonstrated efficacy in patients with BRAF mutant melanoma… (More)
DOI: 10.1517/17425255.2013.794220

1 Figure or Table


  • Presentations referencing similar topics